3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Brain Neoplasms
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasm Metastasis
2
Wilms Tumor
1
Solid Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
9
pembrolizumab
7
Specimen Handling
7
Biopsy
7
Leucovorin
5
Gemcitabine
5
Cisplatin
5
durvalumab
4
Oxaliplatin
4
Fluorouracil
4
Capecitabine
4
Paclitaxel
3
Nivolumab
3
Irinotecan
3
Carboplatin
3
tislelizumab
2
olaparib
2
fludarabine
2
atezolizumab
2
Trastuzumab
2
Taxes
2
Radiation Dose Hypofractionation
2
Radiation
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
zimberelimab
1
varlilumab
1
tucatinib
1
tremelimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Cholangiocarcinoma
×
entrectinib
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA